Chemours Company (0HWG) AI Stock Analysis
Chemours Company
(LSE:0HWG)
No summary available
Chemours Company (0HWG) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $2.04B
- Dividend Yield
- 2.66%
- Average Volume (3M)
- 1,593
- Price to Earnings (P/E)
- -6.8
- Beta (1Y)
- 1.34
- Revenue Growth
- -1.38%
- EPS Growth
- 28.10%
- Country
- UK
- Employees
- 5,700
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
Chemours Company Business Overview & Revenue Model
Company Description
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advan...
Chemours Company Earnings Call Summary
The call highlighted meaningful operational and commercial progress—Q2 adjusted EBITDA beat expectations, TT pricing momentum (≈5% YTD), APM Performance Solutions growth (+8% YoY) and strong cash generation including a ~$270M debt repayment—while also acknowledging notable near-term headwinds, especially TSS aftermarket destocking (pre-buy impact ≈$65M and ~25% YoY market drop), APM volume effects from a prior line closure and TT volume softness amid inflationary input costs. Management reiterated a constructive multi-year view (Pathway to Thrive, $1B adjusted EBITDA ambition) and provided a measured FY 2026 outlook, but near-term guidance incorporates expected sequential declines and ongoing uncertainties.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Chemours guided Q3 consolidated net sales to be down 5% to flat sequentially with consolidated adjusted EBITDA of $175–$205 million, corporate expense of ~$40–$45 million, Q3 CapEx of ~$65 million and at least $50 million of free cash flow; segment guidance was TSS net sales down sequentially mid‑teens to 20% with adjusted EBITDA $125–$140 million, TT net sales up low‑ to mid‑single digits with adjusted EBITDA $70–$80 million, and APM net sales up mid‑ to high‑single digits with adjusted EBITDA $20–$30 million. For full‑year 2026 Chemours expects net sales +1% to +5% versus 2025, adjusted EBITDA $775–$825 million, CapEx $250–$280 million, free cash flow conversion above 25% and net leverage around 3.8x by year‑end; management also reiterated longer‑term targets of at least $1.0 billion of annual adjusted EBITDA and >40% FCF conversion and noted TT pricing actions have driven roughly a 5% YTD TiO2 price increase.
Chemours Company Risk Analysis
Chemours Company disclosed 40 risk factors in its most recent earnings report. Chemours Company reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskChemours Company Peers Comparison
Overall Rating
EMN65Neutral
ASH56Neutral
KRO53Neutral
SOLS50Neutral
WLK49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $7.61B | 11.73 | 10.63% | 5.05% | 0.40% | -6.58% | |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 56Neutral | $3.42B | 65.51 | 2.77% | 2.24% | -1.39% | ― | |
| 53Neutral | $863.23M | -7.88 | -14.34% | 2.67% | 2.70% | -262.08% | |
| 50Neutral | $9.62B | 45.53 | 10.89% | 0.37% | ― | ― | |
| 49Neutral | $8.73B | -7.10 | -13.93% | 3.11% | -3.95% | -1725.20% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0HWG | Chemours Company | 13.42 | 1.48 | 12.36% | |
| ASH | Ashland Global Holdings, Inc. | 74.19 | 27.65 | 59.42% | |
| EMN | Eastman Chemical Company | 66.78 | 8.93 | 15.44% | |
| KRO | Kronos Worldwide | 7.58 | 3.08 | 68.26% | |
| WLK | Westlake Corporation | 71.17 | 6.15 | 9.46% | |
| SOLS | Solstice Advanced Materials, Inc. | 58.93 | 15.42 | 35.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.